Literature DB >> 26697474

NKp30 and its ligands: emerging players in tumor immune evasion from natural killer cells.

Elke Pogge von Strandmann1, Olga Shatnyeva1, Hinrich P Hansen1.   

Abstract

Entities:  

Year:  2015        PMID： 26697474      PMCID： PMC4669320          DOI： 10.3978/j.issn.2305-5839.2015.09.08

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  23 in total

Review 1.  Immune surveillance of unhealthy cells by natural killer cells.

Authors:  Alexandre Iannello; David H Raulet
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2013-10-17

Review 2.  NKG2D Receptor and Its Ligands in Host Defense.

Authors:  Lewis L Lanier
Journal:  Cancer Immunol Res       Date:  2015-06       Impact factor: 11.151

3.  Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack.

Authors:  Wei Wang; Huaijian Guo; Jianlin Geng; Xiaodong Zheng; Haiming Wei; Rui Sun; Zhigang Tian
Journal:  J Biol Chem       Date:  2014-10-14       Impact factor: 5.157

4.  Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding.

Authors:  Helmut R Salih; Hans-Georg Rammensee; Alexander Steinle
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

5.  IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.

Authors:  Stephan Kloess; Sabine Huenecke; Daniel Piechulek; Ruth Esser; Joachim Koch; Claudia Brehm; Jan Soerensen; Tanja Gardlowski; Andrea Brinkmann; Peter Bader; Jakob Passweg; Thomas Klingebiel; Dirk Schwabe; Ulrike Koehl
Journal:  Eur J Immunol       Date:  2010-10-27       Impact factor: 5.532

6.  Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.

Authors:  Elke Pogge von Strandmann; Venkateswara Rao Simhadri; Bastian von Tresckow; Stephanie Sasse; Katrin S Reiners; Hinrich P Hansen; Achim Rothe; Boris Böll; Vijaya Lakshmi Simhadri; Peter Borchmann; Peter J McKinnon; Michael Hallek; Andreas Engert
Journal:  Immunity       Date:  2007-12-06       Impact factor: 31.745

7.  Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.

Authors:  Lizzia Raffaghello; Ignazia Prigione; Irma Airoldi; Marta Camoriano; Isabella Levreri; Claudio Gambini; Daniela Pende; Alexander Steinle; Soldano Ferrone; Vito Pistoia
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

8.  Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.

Authors:  V Veschi; M Petroni; A Bartolazzi; P Altavista; C Dominici; C Capalbo; R Boldrini; A Castellano; H P McDowell; B Pizer; L Frati; I Screpanti; A Gulino; G Giannini
Journal:  Cell Death Dis       Date:  2014-03-06       Impact factor: 8.469

9.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.

Authors:  Cameron S Brandt; Myriam Baratin; Eugene C Yi; Jacob Kennedy; Zeren Gao; Brian Fox; Betty Haldeman; Craig D Ostrander; Tomonori Kaifu; Christian Chabannon; Alessandro Moretta; Robert West; Wenfeng Xu; Eric Vivier; Steven D Levin
Journal:  J Exp Med       Date:  2009-06-15       Impact factor: 14.307

10.  Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function.

Authors:  Venkateswara Rao Simhadri; Katrin S Reiners; Hinrich P Hansen; Daniela Topolar; Vijaya Lakshmi Simhadri; Klaus Nohroudi; Thomas A Kufer; Andreas Engert; Elke Pogge von Strandmann
Journal:  PLoS One       Date:  2008-10-13       Impact factor: 3.240
View more
  9 in total

Review 1.  Insights Into Human Intrahepatic NK Cell Function From Single Cell RNA Sequencing Datasets.

Authors:  Gráinne Jameson; Mark W Robinson
Journal:  Front Immunol       Date:  2021-03-22       Impact factor: 7.561

Review 2.  Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.

Authors:  Matthias Peipp; Katja Klausz; Ammelie Svea Boje; Tobias Zeller; Stefan Zielonka; Christian Kellner
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

Review 3.  A New Biological Feature of Natural Killer Cells: The Recognition of Solid Tumor-Derived Cancer Stem Cells.

Authors:  Rossana Tallerico; Cinzia Garofalo; Ennio Carbone
Journal:  Front Immunol       Date:  2016-05-10       Impact factor: 7.561

Review 4.  Immunomodulation of NK Cells by Ionizing Radiation.

Authors:  Jiarui Chen; Xingyu Liu; Zihang Zeng; Jiali Li; Yuan Luo; Wenjie Sun; Yan Gong; Junhong Zhang; Qiuji Wu; Conghua Xie
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

5.  Clinical Impact of Natural Killer Group 2D Receptor Expression and That of Its Ligand in Ovarian Carcinomas: A Retrospective Study.

Authors:  Gee Hoon Lee; Hee Jung An; Tae Hoen Kim; Gwangil Kim; Kyung Soon Park; Hyun Park; Tae Ho Lee; Ah Young Kwon
Journal:  Yonsei Med J       Date:  2021-04       Impact factor: 2.759

Review 6.  Natural Killer Cells in the Malignant Niche of Multiple Myeloma.

Authors:  Ondrej Venglar; Julio Rodriguez Bago; Benjamin Motais; Roman Hajek; Tomas Jelinek
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

Review 7.  Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.

Authors:  J Obajdin; D M Davies; J Maher
Journal:  Clin Exp Immunol       Date:  2020-07-25       Impact factor: 4.330

8.  Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients.

Authors:  Ali Abouelghar; Reem Hasnah; Ghina Taouk; Mohamad Saad; Manale Karam
Journal:  Oncotarget       Date:  2018-06-05

9.  Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination.

Authors:  David Pejoski; Casimir de Rham; Paola Martinez-Murillo; Francesco Santoro; Floriane Auderset; Donata Medaglini; Gianni Pozzi; Maria Vono; Paul-Henri Lambert; Angela Huttner; Mariëlle C Haks; Tom H M Ottenhoff; Jean Villard; Claire-Anne Siegrist
Journal:  NPJ Vaccines       Date:  2020-04-14       Impact factor: 7.344
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.